Immunology · IL-12/23Regulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for IMULDOSA by Accord Biopharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Accord Biopharma1 signalView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/20/2026, 6:32:14 PM

Assessment confidence: 57% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's acceptance of the supplemental application for IMULDOSA signifies a potential shift in the competitive landscape of the immunology market. This development necessitates close monitoring of the approval timeline and competitive responses from established players in the IL-12/23 space. Regulatory context from FDA (FDA AP — IMULDOSA (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market impact and prepare for competitive responses from established players. The strongest clinical anchor is Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use (ClinicalTrials.gov), moderate corpus alignment. In Immunology · IL-12/23, 8 regulatory and 2 competitive items passed relevance filtering for Accord Biopharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for TZIELD (Teplizumab) Supplement (Humanexa Signals) — mechanism alignment (io ). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This acceptance may enhance Accord Biopharma's position in the immunology market, particularly against competitors in the IL-12/23 space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — IMULDOSA (SUPPL) (FDA). Entity match (accord biopharma). The acceptance of the supplemental application indicates a step towards potential approval, which could influence compliance and labeling strategies for Accord Biopharma.

Key Risks

Elevated medium regulatory exposure for Accord Biopharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, IMULDOSA could capture market share from competitors, impacting revenue streams and positioning within the immunology sector.
Portfolio teams should assess the potential market impact and prepare for competitive responses from established players.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's review process and any subsequent announcements regarding approval status.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — IMULDOSA (SUPPL)
FDAhigh relevance
Entity match (accord biopharma)
FDA document
View source
FDA AP — ENNUMO (ORIG)
FDAhigh relevance
Entity match (accord biopharma)
FDA document
View source
FDA AP — IMMGOLIS (ORIG)
FDAhigh relevance
Entity match (accord biopharma)
FDA document
View source
Investigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — VYEPTI (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — CAPECITABINE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LENALIDOMIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — SPIRONOLACTONE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy of Vitamin D Supplementation to Sustain Performance Outcomes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Near-Infrared Spectroscopy, Acute Taurine Supplementation, and Isolated Muscular Endurance and Fatigue Resistance in Young Healthy Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of the Effectiveness of Physical Therapy for Low Back Pain According to Magnetic Resonance Imaging Findings
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for TZIELD (Teplizumab) Supplement
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Accord Biopharma
IMULDOSA

Commercial impact

medium

If approved, IMULDOSA could capture market share from competitors, impacting revenue streams and positioning within the immunology sector.

Regulatory impact

medium

The acceptance of the supplemental application indicates a step towards potential approval, which could influence compliance and labeling strategies for Accord Biopharma.

What to watch

Monitor the timeline for the FDA's review process and any subsequent announcements regarding approval status.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.